Trial of rPA-102 Vaccine in Healthy Adult Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

July 31, 2005

Conditions
Anthrax
Interventions
BIOLOGICAL

rPA102

Trial Locations (12)

14642

Infectious Disease Unit, University of Rochester Medical Center, Rochester

15241

Primary Physicians Research, Inc., Pittsburgh

21205

Johns Hopkins University, Bloomberg School of Public Health, Baltimore

30322

Emory Children's Clinic, Pediatric Infectious Disease, Atlanta

37232

Vanderbilt University Medical Center, Nashville

43205

Pediatric Clinical Trials Int'l, Inc. (PCTI), Columbus

55905

Mayo Clinic College of Medicine, Rochester

63104

St. Louis University, SoLUtions, St Louis

90502

UCLA Ctr for Vaccine Research, LA Biomedical Research Institute, Torrance

40536-0093

University of Kentucky, Markey Cancer Center, Lexington

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

05405

University of Vermont College of Medicine, Vermont Vaccine Evaluation Center, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Centers for Disease Control and Prevention

FED

lead

VaxGen

INDUSTRY

NCT00100724 - Trial of rPA-102 Vaccine in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter